title: Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
abstract: We report a case of type 1 diabetes mellitus during pegylated interferon and ribavirin treatment for chronic hepatitis C, in a young man previously diagnosed with Hashimoto's thyroiditis and vitiligo. The diabetes mellitus occurred during the 12th month of therapy and the cessation of interferon was necessary. Besides anti-islet autoantibodies our patient had also anti-insulin receptor autoantibodies, which explains the type B insulin resistance. One year after interferon discontinuation the patient continues insulin treatment and all the pancreatic autoantibodies are still positive. Patients with autoimmune disorders should be closely monitored and periodically tested for pancreatic autoantibodies during interferon treatment, even in the absence of hyperglycemia.
authors.affiliation: Prof Dr Matei Bals National Institute of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. gabrielp9@yahoo.com
authors.forename: Cristina
authors.initials: C
authors.lastname: Popescu
authors.forename: Gabriel-Adrian
authors.initials: GA
authors.lastname: Popescu
authors.forename: Victoria
authors.initials: V
authors.lastname: Arama
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000276:immunology; D004359:Drug Therapy, Combination; D050031:Hashimoto Disease / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007333:Insulin Resistance / Q000276:immunology; D016898:Interferon-alpha / Q000009:adverse effects*; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects*; D014820:Vitiligo / Q000150:complications; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D001323:Autoantibodies; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a